Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunocore Holdings PLC Sponsored ADR (IMCR : NSDQ)

• Company Description    Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom. Number of Employees: 493

• Price / Volume Information    Yesterday's Closing Price: $33.09 Daily Weekly Monthly 20 Day Moving Average: 320,768 shares Shares Outstanding: 50.39 (millions) Market Capitalization: $1,667.31 (millions) Beta: 0.79 52 Week High: $39.33 52 Week Low: $23.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.23% -7.95% 12 Week 3.63% -3.95% Year To Date 12.17% -5.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 92 PARK DRIVE MILTON PARK ABINGDON - OXFORDSHIRE,X0 OX14 4RY GBR ph: 44-12-3543-8600 fax: - ir@immunocore.com http://www.immunocore.com

• General Corporate Information    Officers Bahija Jallal - Chief Executive Officer and Director Professor Sir John Bell - Chairman of the Board of Directors Travis Coy - Chief Financial Officer John Goll - Finance and Chief Accounting Officer Roy S. Herbst - Director Peer Information Immunocore Holdings PLC Sponsored ADR (CORR.) Immunocore Holdings PLC Sponsored ADR (RSPI) Immunocore Holdings PLC Sponsored ADR (CGXP) Immunocore Holdings PLC Sponsored ADR (BGEN) Immunocore Holdings PLC Sponsored ADR (GTBP) Immunocore Holdings PLC Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258D105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 50.39 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $1,667.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.29 Price/Cash Flow: - Price / Sales: 4.68 EPS Growth vs. Year Ago Period: 13.04% vs. Previous Quarter: -300.00% Sales Growth vs. Year Ago Period: 29.93% vs. Previous Quarter: 4.35% ROE 09/30/25 - - 06/30/25 - -5.40 03/31/25 - -5.86 ROA 09/30/25 - - 06/30/25 - -1.93 03/31/25 - -2.09 Current Ratio 09/30/25 - - 06/30/25 - 5.89 03/31/25 - 6.36 Quick Ratio 09/30/25 - - 06/30/25 - 5.86 03/31/25 - 6.31 Operating Margin 09/30/25 - - 06/30/25 - -5.70 03/31/25 - -6.48 Net Margin 09/30/25 - - 06/30/25 - -5.70 03/31/25 - -6.48 Pre-Tax Margin 09/30/25 - - 06/30/25 - -6.27 03/31/25 - -6.83 Book Value 09/30/25 - - 06/30/25 - 7.71 03/31/25 - 7.54 Inventory Turnover 09/30/25 - - 06/30/25 - 0.48 03/31/25 - 0.66 Debt-to-Equity 09/30/25 - - 06/30/25 - 1.01 03/31/25 - 1.03 Debt-to-Capital 09/30/25 - - 06/30/25 - 50.23 03/31/25 - 50.85

Powered by Zacks Investment Research ©